文献速递心脑血管急症消化、代谢与肾脏急症

脂蛋白(a)水平与主要不良肢体事件发生率的关联

Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events.
PubMed 文献 · JAMA Netw Open · 2022-12-01
一句话结论住院患者中,高和极高脂蛋白(a)水平与主要不良肢体事件风险独立相关,高Lp(a)组风险约为正常组的1/0.43倍,极高组约为1/0.17倍。

这项在巴黎一家大学医院开展的回顾性单中心队列研究纳入16513例至少检测过一次Lp(a)的住院患者,随访至首次发生主要不良肢体事件(大截肢、外周血管内血运重建或外周外科血运重建)。中位Lp(a)为24 mg/dL。高Lp(a)(50至<134 mg/dL)和极高Lp(a)(≥134 mg/dL)与主要不良肢体事件风险独立相关(校正AFT指数估计分别为0.43和0.17)。总体1年发生率为2.44%,极高Lp(a)组为4.54%。作者认为应重视Lp(a)检测以改善下肢血管风险评估。

要点

  • 在16513例住院患者中,高Lp(a)(50至<134 mg/dL)与主要不良肢体事件风险独立相关,校正AFT指数估计0.43(95%CI 0.24-0.78;Benjamini-Hochberg校正P=0.01)。
  • 极高Lp(a)(≥134 mg/dL)与主要不良肢体事件风险独立相关,校正AFT指数估计0.17(95%CI 0.07-0.40;Benjamini-Hochberg校正P<0.001)。
  • 总体人群主要不良肢体事件1年发生率为2.44%,极高Lp(a)组为4.54%。
  • 主要不良肢体事件定义:随访期间首次住院发生的大截肢、外周血管内血运重建或外周外科血运重建。
  • 作者认为Lp(a)检测需纳入考量,以改善下肢血管风险评估。

适用人群与场景

  • 2000年1月1日至2020年12月31日在巴黎一家大学医院(Hôpital Européen Georges-Pompidou)至少检测过一次Lp(a)的住院患者。
  • 排除无随访数据或首次Lp(a)检测在研究结局发生之后的患者。

诊断标准与关键阈值

  • Lp(a)分类:正常<50 mg/dL,高50至<134 mg/dL,极高≥134 mg/dL。
  • 主要不良肢体事件定义:随访期间首次住院发生的大截肢、外周血管内血运重建或外周外科血运重建。

研究设计与关键结果

  • 研究类型:大型回顾性单中心队列研究,纳入16513例患者,中位(IQR)年龄58.2(49.0-66.7)岁,男性9774例(59.2%)。
  • 中位(IQR)Lp(a)水平为24(10.0-60.0)mg/dL。
  • 主要不良肢体事件1年发生率:总体人群2.44%,极高Lp(a)组4.54%。
  • 高Lp(a)(50至<134 mg/dL)与主要不良肢体事件风险独立相关:校正AFT指数估计0.43(95%CI 0.24-0.78;Benjamini-Hochberg校正P=0.01)。
  • 极高Lp(a)(≥134 mg/dL)与主要不良肢体事件风险独立相关:校正AFT指数估计0.17(95%CI 0.07-0.40;Benjamini-Hochberg校正P<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性单中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,Lp(a)检测需纳入考量,以改善下肢血管风险评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: High lipoprotein(a) (Lp[a]) levels are involved in the development of cardiovascular events, particularly in myocardial infarction, stroke, and peripheral artery disease. Studies assessing the Lp(a) levels associated with adverse lower-limb events are lacking.

OBJECTIVE: To assess the association between Lp(a) levels and incidence of major adverse limb events in unselected hospitalized patients.

DESIGN, SETTING, AND PARTICIPANTS: This large retrospective monocentric cohort study was conducted from January 1, 2000, to December 31, 2020. Data were derived from the clinical information system of the Hôpital Européen Georges-Pompidou, a Paris-based university hospital. Patients who underwent at least 1 Lp(a) measurement at the center during the study period were included. Patients who had no follow-up data or who had the first Lp(a) measurement after the study outcome had occurred were excluded. Data analyses were performed from May 2021 to January 2022.

MAIN OUTCOMES AND MEASURES: The primary outcome was the first inpatient major adverse limb event, defined as a major amputation, peripheral endovascular revascularization, or peripheral surgical revascularization, during follow-up. Secondary outcomes included individual components of the primary outcome. Lipoprotein(a) levels were categorized as follows: normal (<50 mg/dL), high (50 to <134 mg/dL), and very high (≥134 mg/dL); to convert Lp(a) values to milligrams per liter, multiply by 0.1.

RESULTS: A total of 16 513 patients (median [IQR] age, 58.2 [49.0-66.7] years; 9774 men [59.2%]) were included in the cohort. The median (IQR) Lp(a) level was 24 (10.0-60.0) mg/dL. The 1-year incidence of major adverse limb event was 2.44% in the overall population and 4.54% among patients with very high Lp(a) levels. High (adjusted accelerated failure time [AFT] exponential estimate: 0.43; 95% CI, 0.24-0.78; Benjamini-Hochberg-corrected P = .01) and very high (adjusted AFT exponential estimate: 0.17; 95% CI, 0.07-0.40; Benjamini-Hochberg-corrected P < .001) Lp(a) levels were independently associated with an increased risk of major adverse limb event.

CONCLUSIONS AND RELEVANCE: Results of this study showed that higher Lp(a) levels were independently associated with an increased risk of a major adverse limb event in hospitalized patients. The Lp(a) measurement needs to be taken into account to improve lower-limb vascular risk assessment.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Guédon AF, De Freminville JB, Mirault T, et al. Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events. JAMA Netw Open. 2022. PMID: 36480201. doi:10.1001/jamanetworkopen.2022.45720

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。